Broolin Park (MN)-based ShiraTronics is currently conducting a clinical trial in Australia of its implantable system intended for the prophylactic treatment of refractory chronic migraine.
The ShiraTronics System is intended to provide electrical stimulation to nerves associated with migraine pain. The therapy includes a temporary Trial System and a permanent Implant System. The Trial System components include percutaneous leads temporarily placed in the supraorbital and occipital regions. The Implant System components include rechargeable IPGs with integrated leads. The IPGs are implanted in subcutaneous pockets posteriorly on the head with leads tunneled to the supraorbital and occipital regions. Both systems are controlled by a programmer with a therapy application.
The system is approved for clinical trial use only in Australia. ShiraTronics expects to conclude the study started in August 2023 late this year or early next year.